Trial Profile

A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Islatravir (Primary) ; Lenacapavir (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Sponsors Gilead Sciences

07 Nov 2024 According to a Gilead Sciences media release, Late-breaking data from this study will be presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13.
19 Oct 2024 According to Gilead Sciences media release, data from this trial presented at IDWeek 2024
19 Oct 2024 Results published in the Gilead Sciences Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com